Rothschild Investment LLC’s Neurocrine Biosciences NBIX Stock Holding History

Rothschild Investment LLC’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$854K	Buy	5,066 +1,173	+30%	+$174K	0.03%	455
2026 Q1	$513K	Buy	3,893 +828	+27%	+$110K	0.03%	397
2025 Q4	$435K	Buy	3,065 +300	+11%	+$43.5K	0.02%	400
2025 Q3	$388K	Buy	+2,765	New	+$375K	0.02%	412
2025 Q2	–	Sell	-3	Closed	-$332	–	3131
2025 Q1	$332	Hold	3	–	–	﹤0.01%	2739
2024 Q4	$410	Buy	+3	New	+$371	﹤0.01%	2608

Other funds holding NBIX

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

SCP

Seizert Capital Partners Birmingham, Michigan $2.42B AUM 22.12% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Rothschild Investment LLC's NBIX Position: Q2 2026 in Review

Rothschild Investment LLC increased its Neurocrine Biosciences (NBIX) stake by 30% in Q2 2026, buying an estimated $174K and bringing the position to 5,066 shares worth $854K. The position accounts for 0.03% of the portfolio, ranked #455.

Rothschild Investment LLC first reported a position in NBIX in Q4 2024 and has held it in 6 quarters since. 352 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Rothschild Investment LLC held 5,066 shares of Neurocrine Biosciences worth $854K as of Q2 2026.
Rothschild Investment LLC bought 1,173 Neurocrine Biosciences shares in Q2 2026, an estimated $174K.
Neurocrine Biosciences made up 0.03% of Rothschild Investment LLC's portfolio in Q2 2026, its #455 holding.
Rothschild Investment LLC first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 6 quarters since.
352 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.